Up 80% in 2024, here's why the Telix Pharmaceuticals share price is marching higher again on Monday

ASX investors have been piling into Telix Pharmaceuticals shares. But why?

| More on:
Doctor doing a telemedicine using laptop at a medical clinic

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has bounced back into the green today.

Shares in the S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company closed up 15.3% on Friday trading for $18.15 apiece. At the time of writing, in morning trade on Monday, shares are changing hands for $18.21 apiece, up 0.3%.

For some context, the ASX 200 is up 0.9% at this same time.

Friday's big share price leap came after Telix Pharmaceuticals announced positive results from its ProstACT SELECT clinical cancer trial.

Today the company reported on progress on approval for its kidney cancer imaging agent with the United States Food and Drug Administration (FDA).

Here's what investors are considering on Monday.

Telix Pharmaceuticals share price wobbles

Investors are bidding up the Telix Pharmaceuticals share price after the company said it has completed the submission of a Biologics License Application (BLA) to the FDA.

The BLA involves Telix's investigational radiodiagnostic PET agent, TLX250-CDx for the characterisation of renal masses as clear cell renal cell carcinoma (ccRCC). The clear cell variant of renal cancer is the most common and aggressive sub-type of kidney cancer.

The BLA submission was based on Telix's successful global Phase III ZIRCON study in ccRCC.

According to the ASX 200 biotech company, its ZIRCON study met all co-primary and secondary endpoints, demonstrating a sensitivity of 86%, specificity of 87% and a positive predictive value of 93% for ccRCC. That includes patients with small, difficult to detect lesions.

Commenting on the submission helping lift the Telix Pharmaceuticals share price today, chief development officer James Stonecypher said:

Completing the BLA submission for TLX250-CDx represents a significant milestone for Telix as we bring our breakthrough investigational kidney cancer imaging agent closer to market as a non-invasive diagnostic for patients.

We believe TLX250-CDx is a natural follow-on product to Illuccix as it is targeted at the same clinical stakeholders, the urologist and urologic oncologist, and leverages the proven commercial and distribution infrastructure developed through the launch of Illuccix.

The company has also requested a priority review from the FDA as part of its BLA submission process under the eligibility criteria of the Breakthrough Therapy designation.

Management noted that if the FDA grants priority review status, it would potentially support an expedited review time and could further build on the biotech company's successful urology imaging franchise.

If approved, TLX250-CDx will be the first commercially available targeted radiopharmaceutical imaging agent specifically for kidney cancer in the US.

With today's intraday gains factored in, the Telix Pharmaceuticals share price is now up 80% in 2024.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 300 healthcare stock just rocketed 20% on BIG earnings growth

Investors are piling into the ASX 300 healthcare stock on Monday. But why?

Read more »

Health professional putting on gloves.
Earnings Results

Why this ASX 200 share is soaring in Monday's sinking market

The ASX 200 share is shrugging off the broader market fall today to rocket higher. But why?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »